RUBIUS THERAPEUTICS

D.A.A.V. and C.J.W. hold patents on LAG-3, with potential income from licensing. D.A.A.V. has multiple roles in biotech firms and receives funding from BMS and Novasenta. E.J.W. advises and holds stock in several biotech companies. A.H.S. has patents on the PD-1 pathway, receives research funding, and serves on various advisory boards. A.R.C. consults for Abound Bio.

The Global Immuno-oncology Clinical Trials Market is projected to grow from USD 6.13 billion in 2023 to USD 12.87 billion by 2030, at a CAGR of 11.17%. The report analyzes market dynamics, competitive landscape, and profiles key vendors like AstraZeneca and BioNTech. It covers market segmentation by design, phase, indication, and regional prospects including North America, Asia-Pacific, and EMEA.